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Background: Methionyl-tRNA synthetase (MARS) catalyzes the ligation of methionine to its cognate transfer RNA
and therefore plays an essential role in protein biosynthesis.
Methods: We used exome sequencing, aminoacylation assays, homology modeling, and immuno-isolation of
transfected MARS to identify and characterize mutations in the methionyl-tRNA synthetase gene (MARS) in an infant
with an unexplained multi-organ phenotype.
Results: We identified compound heterozygous mutations (F370L and I523T) in highly conserved regions of MARS.
The parents were each heterozygous for one of the mutations. Aminoacylation assays documented that the F370L
and I523T MARS mutants had 18 ± 6% and 16 ± 6%, respectively, of wild-type activity. Homology modeling of the
human MARS sequence with the structure of E. coli MARS showed that the F370L and I523T mutations are in close
proximity to each other, with residue I523 located in the methionine binding pocket. We found that the F370L and
I523T mutations did not affect the association of MARS with the multisynthetase complex.
Conclusion: This infant expands the catalogue of inherited human diseases caused by mutations in aminoacyl-
tRNA synthetase genes.
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Aminoacyl-tRNA synthetases (ARSs) are a family of en-
zymes that covalently attach transfer RNA (tRNA) and
amino acids. The various ARSs function either in the cyto-
plasm or in mitochondria although in some cases they act
in both compartments (i.e. bifunctional). Mutations in cyto-
plasmic and bifunctional ARSs have been identified in
Charcot-Marie-Tooth disease (ARS for alanine (AARS),
lysine (KARS), tyrosine (YARS) and glycine (GARS)) and
distal spinal muscular atrophy type V (GARS) [1]. Interest-
ingly, while these ARSs are ubiquitously expressed, these
diseases are characterized by neurodegeneration and neur-
opathy. Also, cytoplasmic DARS mutations have been* Correspondence: cole@kids.wustl.edu
2Division of Newborn Medicine, Edward Mallinckrodt Department of
Pediatrics, Washington University School of Medicine, St. Louis, MO
63110, USA
Full list of author information is available at the end of the article
© 2013 van Meel et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the oridentified in recessive neurologic phenotypes [2] and HARS
mutations in patients with peripheral neuropathy [3].
However, the disease phenotype associated with ARSs
is expanding. For example, a recent report described a
family kindred with infantile hepatopathy, anemia,
renal tubulopathy, developmental delay, seizures and
unusual fingers due to mutations in the gene that en-
codes cytoplasmic leucyl-tRNA synthetase (LARS) [4].
In this study we identified loss-of-function mutations in
the gene encoding MARS, the cytoplasmic methionyl-
tRNA synthetase, which couples methionine to tRNA, in
an infant with a multi-organ phenotype similar to that ob-
served in the patients with LARS mutations. The identified
mutations significantly impaired MARS’ ability to ligate
methionine to its cognate tRNA and are therefore likely
responsible for the patient’s phenotype. This report pro-
vides additional evidence that mutations in cytoplasmical Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
van Meel et al. BMC Medical Genetics 2013, 14:106 Page 2 of 10
http://www.biomedcentral.com/1471-2350/14/106ARSs can lead to a variety of clinical manifestations be-
yond the nervous system.
Case presentation
The female infant was the 2,500 g non-consanguineous
product of a 36-week gestation in a 29-year-old primi-
gravida woman. Paternal age was 29 years. Both parents
were healthy without clinical evidence of neuropathy, and
the family histories did not include first degree relatives
with neurodegenerative or neuropathic syndromes or chil-
dren with multi-organ failure. An evaluation was done at
1 month due to the failure to gain weight (60 g weight
gain since birth) along with vomiting and mild hypotonia.
The newborn screen was normal as were liver enzymes,
but episodic hyperammonemia was noted along with
anemia (hemoglobin 8.3 g%) with thrombocytosis (plate-
lets 790,000/mm3) (Additional file 1: Table S1). An upper
gastrointestinal series was normal.
Between 3 and 9 months of age, the infant failed to
gain weight (weight and head circumference less than
3rd percentile) and developed liver failure, intermittent
lactic acidosis, aminoaciduria, hypothyroidism, interstitial
lung disease and transfusion-dependent anemia. Develop-
mental delay (motor) and hypotonia were present, but MRI
of the brain was normal. Bone marrow biopsy at 3 months
showed arrest of RBC maturation (Figure 1A). Liver biopsy
at 5 months revealed cholestasis, steatosis, bridging necro-
sis, minimal fibrosis, hemosiderin-laden macrophages in
the portal tracts and normal appearing mitochondria
(Figure 1B-C). Electron microscopy of the liver biopsy did
not reveal diagnostic abnormalities (Figure 1C). Muscle
biopsy revealed marked excess of type IIC muscle fiber con-
sistent with mitochondrial disorders, but electron microscopic
examination showed normal mitochondrial appearance.
Succinate dehydrogenase and cytochrome C oxidase immu-
nostaining in muscle was normal and genetic analysis ex-
cluded major mitochondrial rearrangements, including
Pearson’s deletion, while DNA sequence analysis failed
to identify pathogenic mutations in mitochondrial genes.
Further, there was no evidence of a mitochondrial respira-
tory chain defect in muscle and liver tissues. Taken together
these data excluded a primary mitochondrial disorder. Fur-
ther evaluation excluded other known metabolic and gen-
etic causes of this type of multi-organ phenotype (Table 1).
Total parenteral nutrition (TPN) was started at age
4 months. At approximately 9 months of age the infant
began to gradually improve becoming transfusion-
independent and exhibiting normalization of liver func-
tion. However, at 3.5 years of age she remains dependent
on TPN and nasal cannula oxygen, is less than 3rd per-
centile for weight and head circumference, continues on
thyroid replacement and has motor (but not cognitive)
delay. Recent formal neurological assessment (age 3 years
9 months) including neurocognitive testing revealedmotor delay and appropriate verbal and intellectual abil-
ities. The patient has not undergone nerve conduction
studies to assess her motor delay.
Methods
Antibodies and reagents
Rabbit anti-human MARS antibody (HPA004125) and
rabbit anti-actin antibody (A2066) were obtained from
Sigma (St. Louis, MO). Rabbit anti-human RARS anti-
body (ab31537) and rabbit anti-human KARS antibody
(ab31532) were from Abcam (Cambridge, MA). Horse-
radish peroxidase linked donkey anti-rabbit IgG (GE
Healthcare Biosciences, Pittsburgh, PA) was used as sec-
ondary antibody in western blotting. L-methionine [me-
thyl-3H] with specific activity of 1.0 Ci/mmol was
purchased from MP Biomedicals (Santa Ana, CA). Total
tRNA type XI purified from bovine liver was from Sigma
and calf liver tRNA from Novagen (kind gift from M.
Boniecki/S. Martinis, University of Illinois, Urbana, IL).
FLAG peptide was generated by Biomolecules Midwest
Inc. (Waterloo, IL). All other reagents were from Sigma
(St. Louis, MO), unless otherwise indicated.
Exome sequencing
Genomic DNA was isolated from the patient’s blood using
the Gentra Puregene blood kit (Qiagen, Germantown,
MD) and from the parents’ saliva with Oragene collection
kits (DNA Genotek Inc., Kanata, Canada). Exome targets
were enriched with the SureSelect Human All Exon kit
(38 MB version, Agilent Technologies, Santa Clara, CA),
according to the manufacturer’s protocols and Illumina se-
quencing adapters (Illumina, Inc., San Diego, CA) were
added to each sample to create sequence ready libraries.
After sequencing with an Illumina HiSeq 2000 sequencing
instrument the 2×101 bp paired-end sequencing reads
were aligned to the human genome (reference build hg19)
with Novoalign (Novocraft Technologies, Petaling Jaya,
Malaysia) and genetic variants were identified with
SAMtools [5]. Annovar [6] was used to annotate function
of genetic variants and public databases (Exome Seq-
uencing Project) to select rare variants (minor allele
frequencies < 0.05). To predict deleterious effects of non-
synonymous variants Annovar downloads data from
dbNSFP [7], which recompiles prediction scores from four
programs (SIFT, Polyphen2, LRT, and MutationTaster) as
well as a conservation score (PhyloP). Species alignment
was performed with Alamut (Interactive Biosoftware,
San Diego, CA). Variant data for individuals of European
descent (n = 4300) from the Exome Sequencing Project
were annotated and selected in the same manner as
the patient’s and parents’ exome sequencing data and
used to estimate potential disease prevalence by calcu-




Figure 1 Liver and bone marrow pathology. A: The patient’s bone marrow (left photo) contains megakaryocytes (arrow) and numerous
myeloid cells (chevron), while erythroid cells are difficult to identify. In contrast, erythroid cells (curved arrows) are readily apparent in control
bone marrow (right photo). B: The patient’s liver (left photo) shows lobular disarray with hepatocyte ballooning (arrowhead), canalicular
cholestasis (arrow) and zone 1 steatosis (chevron). Iron deposition (star) is present in macrophages and hepatocytes. Control liver (right photo) for
comparison. C: Electron micrograph of hepatocyte shows mild pleomorphism of mitochondria (arrows), which contain predominantly flattened,
straight and curved cristae. These are non-specific findings that can be seen in normal liver.
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Table 1 Diagnostic evaluation in a patient with MARS mutations
Disorders investigated Investigations performed (normal unless otherwise indicated)
General investigations • Serology for Hepatitis B, C, EBV, CMV; PCR for HIV
• Alpha-1-antitrypsin and Pi type
• Sweat test
• Chromosomal microarray analysis: Paternally inherited duplication of 3p14.2 (616 kb) including C3orf67
• Immunoglobulin levels, neutrophil oxidative burst activity, lymphocyte subpopulations
Disorders of intermediary metabolism • Glucose, creatine kinase
• Serum amino acids including homocysteine
• Urine organic acids (including succinylacetone)(during liver failure, tyrosine metabolites but not
succinylacetone observed)
• Serum ceruloplasmin, serum and urine copper
• Serum iron profile: Iron 65 μg/dl (nl 50-120); iron binding capacity, unsaturated <20 μg/dl (nl 100-400),
iron binding capacity total 40 μg/dl (nl 250-450), transferrin saturation 162% (nl 10-45);
ferritin 1053 ng/ml (nl 50-200)
• Galactosemia metabolic panel (GALT, Gal-1 PO4 levels and DNA testing)
• Acylcarnitine profile
Disorders of energy metabolism • Glucose profiling; lactate 3.4 mmol/L (nl 0.5-1.5), pyruvate 0.32 mmol/L (nl 0.03-0.08); CSF lactate 3.5,
CSF pyruvate 0.19
• Muscle biopsy: histology, histochemistry, electron microscopy, respiratory chain enzyme analysis,
muscle mtDNA content, mtDNA analysis for deletions and rearrangements, mtDNA sequencing
• Muscle biopsy: excess of type IIC muscle fibers, immunostaining for succinate dehydrogenase and
cytochrome c oxidase normal, normal mitochondrial appearance by electron microscopy
• DGUOK, MPV17, and POLG1 sequencing
• Ornithine decarbamylase gene sequencing
• Liver biopsy: cholestasis, steatosis, bridging necrosis, minimal fibrosis, hemosiderin laden macrophages
in the portal tracts, and normal appearing mitochondria and electron microscopy (Figure 1B-C),
liver respiratory chain analysis, liver mtDNA content
• Urine sugar and polyol and plasma sterol analyses
• Initial aminoaciduria resolved
• BCS1L sequencing for GRACILE (growth retardation, aminoaciduria, cholestasis, iron overload, lactacidosis,
and early death) syndrome
• Ophthalmology and cardiology assessments
• MRI and CT scan of brain
Disorders of complex molecules • Isoelectric focusing consistent with liver failure
• White cell lysosomal enzyme screen
• Wolman disease (lysosomal acid lipase deficiency)
• Lysinuric protein intolerance (SLC7A7)
• Urine mucopolysaccharides and oligosaccharides
• Niemann-Pick types A and B (sphingomyelinase deficiency), and C (fibroblasts), GM1 gangliosidosis,
and Gaucher disease
• Bone marrow aspirate: RBC maturation arrest (precursors but not mature RBCs present);
normal 5’nucleotidase
• Plasma very long chain fatty acid analysis
• Plasma and urine bile acid analysis, plasma cholesterol
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Human MARS cDNA (NM_004990.3) in pCMV6-AC
was obtained from OriGene Technologies, Inc. (Rockville,
MD). MARS mutants F370L and I523T were generated by
quick change mutagenesis, using the primers 5′-CCAAAA TCA CCC AGG ACA TTC TCC AGC AGT TGC
TGA AAC G-3′ and 5′-CGT TTC AGC AAC TGC TGG
AGA ATG TCC TGG GTG ATT TTG G-3′ for F370L
MARS and the primers 5′-CTG GTT TGA TGC CAC
TAC TGG CTA TCT GTC CAT C-3′ and 5′-GAT GGA
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for I523T MARS. For purification, a C-terminal FLAG
sequence was introduced by PCR with the following
primers 5′-CCG CTC GAG GCC ACC ATG AGA CTG
TTC GTG AGT G-3′ and 5′-CCC AAG CTT TTA
CTT GTC ATC GTC GTC CTT GTA GTC CTT TTT
CTT CTT GCC-3′. Wild-type, F370L or I523T MARS-
FLAG was excised with XhoI and HindIII and inserted
into pcDNA3.1(−).
Aminoacylation assay
HEK293 cells were cultured in 6-well plates in Dulbecco’s
Modification of Eagle’s Medium (DMEM, Cellgro,
Mediatech, Inc., Manassas, VA) containing 4.5 g/L glu-
cose with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA), L-glutamine (Cellgro) and penicillin/
streptomycin (Invitrogen, Carlsbad, CA). The cells were
transfected with pCMV6-AC that encoded wild-type,
F370L or I523T MARS, or mock transfected using
Lipofectamine Plus reagent (Invitrogen) according to the
manufacturer’s protocol. Nineteen hours after transfection
the cells were lysed in 1% Triton-X100 in 25 mM HEPES,
pH = 7.9, containing 10% glycerol and a protease inhibitor
cocktail (Complete, Roche Diagnostics, Indianapolis, IN).
The protein concentration was determined via the
Bradford protein assay and 20 μg was added to the re-
action mixture, which contained 25 mM HEPES, 3 mM
MgCl2, 2 mM DTT, 2 mM ATP, 160 μg tRNA, 1 μCi of
[3H]-methionine in a final concentration of 50 μM, 10%
glycerol, pH = 7.9, in a total volume of 100 μL. The reac-
tions were incubated at room temperature for 10 minutes
(time course studies showed that the reaction was still
linear at this incubation period), after which the reaction
mixture was spotted on filter pads (Whatman, grade 3,
GE Healthcare UK Limited, Little Chalfont, UK) that
had been pre-wetted in 5% trichloroacetic acid and dried.
The filter pads were washed 3 times in 5% trichloroacetic
acid, once in 70% ethanol and subsequently dried and
counted in a scintillation counter. The values obtained
with mock transfected cell lysates were subtracted from
the values obtained with wild-type or mutant MARS ex-
pressing cells to correct for endogenous enzyme activity
and non-specific background counts. MARS expression in
HEK293 lysates was verified by subjecting 10 μg of lysate
to SDS-PAGE and western blotting.
MARS purification
Wild-type, F370L or I523T MARS-FLAG cDNAs in
pcDNA3.1(−) were expressed in HEK293 cells as de-
scribed. After lysis in 1% Triton-X100/25 mM HEPES,
pH = 7.9/10% glycerol containing protease inhibitors, the
lysates were incubated with anti-FLAG M2 affinity gel
for 2 h at 4°C, while rotating. Subsequently, the beads
were washed with cold PBS and bound protein waseluted from the beads by incubation with 0.5 mg/ml
FLAG peptide in 25 mM HEPES/10% glycerol at 4°C on
a rotor. After 45 minutes the beads were spun down and
the supernatant, containing FLAG-tagged MARS, was
collected. The eluted fractions were separated by SDS-




Chromosomal microarray analysis revealed a 616 kb du-
plication of chromosome 3 (3p14.2) (data not shown).
This region contains only one gene (C3orf67). Since the
father had the same duplication and was asymptomatic
and the mother had no evidence of disruptive variants in
this region, we reasoned that the duplication was un-
likely to be responsible for this patient’s disorder. There-
fore, to identify candidate gene mutations, we sequenced
the exomes of the patient and her parents. In total,
17,988 variants (single nucleotide polymorphisms and
small insertions/deletions) were identified in the patient,
and various computational filtering criteria were used to
select candidate genes. Recessive inheritance of rare mu-
tations was assumed, and variants that were non-exonic,
synonymous or present at frequencies ≥ 0.05 in the
Exome Sequencing Project database were excluded.
Furthermore, only non-synonymous variants predicted
to be functional by at least 4 of the 5 functional predic-
tion algorithms in Annovar [6] were selected. Finally,
only genes were selected in which multiple loss of func-
tion alleles were present. Genes with de novo mutations
were also included. This filtering strategy resulted in the
identification of a single gene, MARS (NM_004990.3),
which encodes methionyl-tRNA synthetase. The patient
was compound heterozygous for two missense muta-
tions, c.1108 T > C in exon 10, resulting in F370L and
c.1568 T > C in exon 13, changing Ile at 523 to Thr
(Figure 2A). Each parent was heterozygous for one of
the mutations; the father carried c.1108 T > C, and the
mother c.1568 T > C (Figure 2A). Sanger sequencing con-
firmed both mutations in the patient and her parents.Effect of mutations on MARS expression and activity
Alignment of human MARS with MARS from different
species showed that both mutated residues are located
in highly conserved regions (Figure 2B). Phenylalanine at
position 370 in human MARS was conserved in all spe-
cies that were analyzed with the exception of E. coli,
which has a similar hydrophobic residue, i.e. tyrosine.
Isoleucine at position 523 was conserved in all species
except in Drosophila melanogaster, which has phenyl-
alanine at this position (Figure 2B). Moreover, both mu-
tations are present in the catalytic domain of MARS
Figure 2 Exome sequencing reveals mutations in highly conserved regions of the catalytic domain of MARS. A: MARS mutations in the
patient and her parents. The patient is compound heterozygous for the mutations c.1108 T > C, F370L (paternally inherited) and c.1568 T > C,
I523T (maternally inherited), see arrows. B: Protein sequence alignment of MARS orthologs. The mutated residues are indicated by arrows and
marked in red when conserved. C: Schematic representation of the different domains of MARS. The locations of the mutations, which are in the
catalytic domain (orange), are indicated by arrows. The GST-like domain is shown in blue and the tRNA binding domain in green.
Figure 3 MARS mutations F370L and I523T significantly impair
MARS activity. A: F370L and I523T MARS are expressed in HEK293
cells. Western blots show that wild-type and the mutant forms of
MARS were expressed at similar levels (upper panel) with equal
amounts of protein loaded, as reflected by the equal levels of actin
(lower panel). Endogenous MARS in mock treated cells was only
detected after prolonged exposure (see Additional file 2: Figure S1).
B: Measurement of MARS activity, using the aminoacylation assay,
shows greatly reduced activity of both MARS mutants. The activities
of F370L and I523T MARS are represented as the percentages of
wild-type MARS activity (set to 100%). The values are the averages of
3 independent experiments, ± the standard deviations.
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on MARS aminoacylation function.
To determine whether the mutations impaired MARS
activity we measured the ability of the various forms of
MARS to couple [3H]-methionine to tRNA in an in vitro
aminoacylation reaction. We initially assayed extracts of
patient and control fibroblasts, but the MARS activity in
these samples was too low to obtain valid data. For this
reason, we generated plasmids encoding human wild-
type, F370L or I523T MARS and used these to transfect
HEK293 cells. After 16 h, cell lysates were examined for
MARS expression by western blotting. Similar levels
of wild-type, F370L and I523T MARS were detected
(Figure 3A; Additional file 2: Figure S1), indicating that
the MARS mutations did not impair expression or
half-life of the enzyme. Whole cell lysates with equal
amounts of MARS were then used in the aminoacylation
assay. Both mutants had detectable, but low levels of
activity compared to wild-type MARS. The F370L mu-
tant had 18 ± 6% and the I523T mutant had 16 ± 6% of
wild-type activity (Figure 3B), demonstrating that each
mutation significantly reduces the ability of MARS to
couple methionine to its cognate tRNA.
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mutations, human MARS was modeled on the structure
of E. coli MARS [8], which shares 28% identity and 48%
similarity with the human MARS sequence (Figure 4A).
This homology modeling revealed that residue I523 is
located in an alpha-helix that is part of the methionine
binding pocket that contains several residues that dir-
ectly interact with methionine (Figure 4B). While I523 is
not directly involved in methionine binding, its close
proximity to residues that are critical for this binding
suggests that the mutation could affect this interaction.
The presence of F370 in an alpha-helix close to I523
(Figure 4C) could explain the effect of mutation of this
residue on MARS activity.
MARS mutations do not impair multisynthetase complex
assembly
MARS, along with eight other synthetases and three non-
enzymatic cofactors, is known to form a multisynthetase
complex [1]. While the role of the complex has remained
elusive, several potential functions have been proposed [9].
It was therefore of interest to determine whether the mu-
tations in MARS altered its incorporation into the com-
plex. To do this, FLAG-tagged wild-type, F370L and
I523T MARS cDNAs were generated and expressed in
HEK293 cells. Subsequently, MARS was immuno-isolated,
and the co-purified proteins were visualized by Coomassie
staining (Figure 5A; Additional file 3: Figure S2). In all
three instances, a staining pattern consistent with the
multisynthetase complex was observed [10]. Western blot-
ting identified two ARSs that are known components ofFigure 4 Location of the mutated residues I523 and F370 in human M
MARS (pink, PDB 1PFU) in complex with methionine phosphinate (grey, wi
(sulfur) and blue (nitrogen)). B: Close-up of the methionine binding pocket
(pink). Residue I523 of human MARS (purple sticks) is located close to the m
methionine. C: Residue F370 (purple sticks) is located in an alpha-helix closthe complex, i.e. lysyl-tRNA synthetase (KARS) and
arginyl-tRNA synthetase (RARS) (Figure 5B). These data
show that while the F370L and I523T mutations impair
MARS activity, they do not prevent its association with
the multisynthetase complex.
Discussion
In this study, we identified two mutations in the gene
encoding MARS in an infant with an unexplained disorder.
Since each mutation significantly reduces MARS activity,
they are likely responsible for the multi-organ phenotype
observed in the patient. The lack of symptoms in her
heterozygous parents indicates that a predicted ~40%
reduction of MARS activity is well tolerated. While the
mutations impair the catalytic activity, they do not affect
the association of MARS with the multisynthetase com-
plex. This finding is in agreement with a previous study,
which showed that the N-terminal GST-like subdomain
of MARS is required for its association with the complex
[11]. Since the role of the multisynthetase complex is un-
clear, it is not possible to know at this point whether the
MARS mutations have any negative consequences on
the function(s) of the complex. In addition, a paternally
inherited 616 kb duplication of 3p14.2 was observed in
the patient. Although the father was unaffected and no
maternal potentially trans-acting mutations were noted
in the region of this duplication, we cannot exclude the
possibility that the duplication contributes in some way
to the patient’s phenotype.
Due to the unique characteristics of this patient’s pheno-
type, searching for other patients with MARS mutationsARS. A: Homology modeling of human MARS (purple) with E. coli
th elements colored in red (oxygen), orange (phosphorus), yellow
. Residues that interact with methionine are represented by sticks
ethionine binding pocket, but does not directly interact with
e to residue I523.
Figure 5 F370L and I523T MARS associate with the
multisynthetase complex. A: Coomassie staining of wild-type,
F370L and I523T MARS-FLAG purified fractions. MARS-FLAG is
indicated (arrow). The asterisk shows a degradation product of MARS
(~75 kD), which is more pronounced after purification of wild-type
MARS-FLAG. However, the ratio of the 100 kD full length MARS and
the partially degraded form was not established in the wild-type
and MARS mutants. MARS was not immunoprecipitated from cell
lysates that expressed I523T MARS-FLAG with a nonsense mutation
in the FLAG tag that abolished binding to the anti-FLAG antibody
(see Additional file 3: Figure S2). B: Components of the
multisynthetase complex are co-purified upon immuno-isolation of
wild-type, F370L or I523T MARS. Western blotting shows the
presence of similar levels of MARS, KARS and RARS (upper, middle
and lower panel, respectively) after immuno-isolation of MARS-FLAG
from HEK293 cells.
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disease prevalence due to MARS mutations we used vari-
ant data from the Exome Sequencing Project (Exome Vari-
ant Server, NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA (URL: http://evs.gs.washington.edu/EVS/;
n = 4,300 European descent individuals) (Downloaded
August 20, 2012). After variant filtering, we identified 33
predicted loss-of-function alleles. Assuming Annovar ac-
curately predicts loss of function, and that mutations are
not embryonic or fetal lethal or associated with variable
phenotypes, we estimated a maximum disease frequency
associated with loss of MARS function at 1.5 /100,000
individuals, or approximately 33 cases/year from an an-
nual U.S. European descent birth cohort of approximately
2,200,000 [12]. Confirmation of causality by discovery of
MARS mutations in a cohort of patients with similar, rare
phenotypes was not possible.
Surprisingly, the condition of the patient began to
improve at approximately 9 months of age. While the
explanation for her improvement is unclear, we consid-
ered the possibility that the initiation of parenteral nutri-
tion may have contributed to the improvement. Since the
mutated residues present in the patient’s MARS are closeto the methionine binding pocket, we hypothesized that
the mutations might impair methionine binding. In that
scenario, increased methionine intake via parenteral nu-
trition might improve MARS aminoacylation function.
However, when we tested this hypothesis in fibroblasts
obtained from the patient, we were unable to find any
clear indication that their slow growth rate was altered
in the presence of higher concentrations of methionine
(data not shown).
Based on the observation that mutations in cytoplasmic
ARSs result in neurologic phenotypes, it was postulated
that ARSs may be particularly important for the develop-
ment and function of neurons, and that mutations in all
ARSs may result in neurological disease [1]. However,
more recently it has become clear that mutations in mito-
chondrial ARSs result in more heterogeneous phenotypes
(SARS2, AARS2, HARS2, LARS2 and YARS2 mutations)
[13-17] that may include neurologic phenotypes (MARS2,
RARS2, FARS2, DARS2 and EARS2) [18-23]. Interestingly,
our patient’s phenotype has characteristics similar to the
phenotype recently observed in an Irish Traveller family
kindred characterized by hepatopathy in the first 6 months
of life and associated with homozygous, novel or rare,
loss-of-function mutations in the gene that encodes LARS
[4]. Similar to our MARS mutation patient, the LARS pa-
tients exhibited anemia, renal tubulopathy, developmental
delay, failure to thrive, hepatopathy and unusual fingers.
However, our patient has distinct differences from the
LARS patients including interstitial lung disease, hy-
pothyroidism and normal brain MRI. These phenotypic
differences may be attributable to differences in require-
ment for the two ARSs, different levels of residual activity
or genetic background differences. Interestingly, among
patients with autoimmune antisynthetase syndromes, an-
tibodies against aminoacyl-tRNA synthetases strongly
predict interstitial lung disease [24-26]. Our patient’s inter-
stitial lung disease may reflect a mechanistically distinct
but functionally similar disruption of MARS.Conclusions
The current study shows that loss-of-function of MARS,
a cytoplasmic ARS, causes a multi-organ disorder with
greater impact on liver, bone marrow, lung and thyroid
function than on neuronal function during infancy.
After submission of this manuscript, Gonzalez et al.
reported two male family members with late onset
Charcot-Marie-Tooth disease who are heterozygous for
a R618C missense mutation in MARS [27]. The Arg618
residue is located in the catalytic domain of the enzyme
and the Cys substitution results in impaired activity as
measured in a yeast rescue assay. In view of this report,
regular surveillance for neuropathy in this patient and
the parents will be important.
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Additional file 1: Table S1. Multi-organ dysfunction in a patient with
MARS mutations.
Additional file 2: Figure S1. Endogenous MARS is detected in HEK293
cells. HEK293 cell lysates that were mock transfected or transfected with
wild-type, F370L or I523T MARS were subjected to SDS-PAGE and anti-MARS
western blotting. Prolonged exposure shows the presence of endogenous
MARS in the mock transfected cells.
Additional file 3: Figure S2. F370L and I523T MARS associate with the
multisynthetase complex. As a control, HEK293 cells were transfected
with a construct encoding I523T MARS with a mutation in the FLAG-tag
that abolished binding to the anti-FLAG antibody. The anti-FLAG
immunoprecipitates of lysates of these cells showed two Coomassie
staining background bands (arrows), but lacked the MARS band and the
other components of the complex.
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